NEUROCRINE BIOSCIENCES INC (NBIX): SEC Filings & AI Analysis
Healthcare. Latest 10-K, 10-Q, and 8-K filings for NEUROCRINE BIOSCIENCES INC (NBIX) with AI risk scoring and cited answers, grounded in primary-source SEC EDGAR data.
Most recent filing — 8-K filed September 28, 2026: BULLISH Concern level: MODERATE.
Company overview — key questions
Answers are generated from SEC filings and StockHuntr's analysis. Not investment advice.
What is NEUROCRINE BIOSCIENCES INC (NBIX)?
NEUROCRINE BIOSCIENCES INC is a publicly traded company in the Healthcare space tracked on StockHuntr, which analyzes its SEC filings (10-K, 10-Q, 8-K) and generates 30-day stock predictions.
What are NBIX's most recent SEC filings?
Recent filings: 8-K (September 28, 2026).
What does NBIX's latest filing analysis show?
NBIX's most recent 8-K (September 28, 2026) is rated BULLISH, concern level MODERATE.
Is NBIX a buy?
StockHuntr doesn't issue buy or sell ratings — it's a research tool. For NEUROCRINE BIOSCIENCES INC (NBIX), its latest 8-K is rated MODERATE concern. Weigh these filing-based signals alongside your own research. This is model analysis for research, not investment advice.
Recent NBIX filings analyzed
- 8-K · Sep 28, 2026 · concern 2.1/10
Other Healthcare companies
About this analysis
- Primary source:
- View this company's filings on SEC EDGAR
- Additional data:
- Yahoo Finance (market data)
- Method:
- StockHuntr analyzes filings with AI — see our methodology.
- Analysis as of:
- September 28, 2026
- Published by:
- StockHuntr
For research and education only. Nothing here is investment advice.
Loading NBIX snapshot...
Fetching live market data